Want to see JP:4552 full AI Analyst Report?

JCR Pharmaceuticals Co., Ltd. (4552) Price & Analysis

1 Followers

4552 Stock Chart & Stats

¥712.00

-¥21.00(-3.43%)

At close: Jan 08 4:00 PM EST

¥712.00

-¥21.00(-3.43%)

Day’s Range― - ―

52-Week Range¥444.00 - ¥824.00

Previous CloseN/A

Volume326.50K

Average Volume (3M)578.69K

Market Cap

¥56.43B

Enterprise Value¥96.37B

Total Cash (Recent Filing)¥13.18B

Total Debt (Recent Filing)¥40.10B

Price to Earnings (P/E)25.5

Beta0.88

Next Earnings

Jul 29, 2026

EPS Estimate

-11.27

Next Dividend Ex-DateN/A

Dividend Yield2.71%

Share Statistics

EPS (TTM)-45.01

Shares Outstanding129,686,310

10 Day Avg. Volume668,090

30 Day Avg. Volume578,686

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)1.48

Price to Sales (P/S)1.72

P/FCF Ratio-5.99

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥560.00

Price Target Upside-21.35% Downside

Rating ConsensusHold

Number of Analyst Covering6

EPS Forecast (FY)3.43

Revenue Forecast (FY)¥45.51B

Bulls Say, Bears Say

Bulls Say

Specialty Biologics FocusJCR’s concentration on specialty biologics and rare-disease therapies creates durable barriers to entry, more predictable reimbursement pathways, and patient stickiness. This strategic focus supports sustained demand, differentiated pricing, and long-term commercial stability versus commodity pharma segments.

In-house Manufacturing / CMO CapabilityOwning production capacity gives JCR a structural advantage: it diversifies revenue via contract manufacturing, improves control over supply and quality for biologics, and enhances margin capture on proprietary products. This capability supports scalable commercialization and partner monetization over multiple years.

Revenue Rebound In FY2026A ~20% revenue rebound in FY2026 demonstrates commercial resilience and recovery of demand after a prior decline. Restored topline momentum increases the likelihood of margin normalization, steadier cash conversion, and improved capacity to fund R&D and growth initiatives sustainably.

Bears Say

Negative Operating And Free Cash FlowSustained negative operating and free cash flow raises funding and execution risk: it pressures liquidity, increases reliance on external financing, and can force cuts to R&D or capital programs. Persistent cash burn undermines the firm's ability to invest organically or pursue strategic deals without diluting stakeholders.

Rising LeverageA meaningful rise in debt reduces financial flexibility and elevates interest and refinancing risk. Higher leverage constrains investment capacity, heightens sensitivity to margin pressure or reimbursement shifts, and limits the company’s ability to respond to adverse industry developments over the medium term.

Volatile ProfitabilityLarge year-to-year swings in profitability weaken earnings quality and forecasting reliability. This volatility complicates long-range planning, increases the risk premium for partners and lenders, and may reflect exposure to one-offs, pricing pressure, or inconsistent product mix that could persist absent structural fixes.

JCR Pharmaceuticals Co., Ltd. News

JCR Pharmaceuticals Corrects FY2025 Results as Profit Rebounds and Dividend Held Steady

An update from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) is now available. JCR Pharmaceuticals has announced partial...

9d ago

4552

JCR Pharmaceuticals Corrects FY2024 Results as Weak Performance Prompts Closer Scrutiny

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has issued an announcement. JCR Pharmaceuticals has issued a partial correction...

9d ago

4552

JCR Pharmaceuticals to Grant Restricted Treasury Shares as Long-Term Incentive

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has issued an announcement. JCR Pharmaceuticals has approved the disposition of...

9d ago

4552

JCR Deepens Strategic Alliance With Major Shareholder MEDIPAL While Maintaining Independence

An update from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) is now available. JCR Pharmaceuticals detailed its relationship...

9d ago

4552

JR-446 Trial Signals Early Rare-Disease Catalyst for Medipal and JCR

Medipal Holdings Corporation ($MEPDF), JCR Pharmaceuticals Co., Ltd. ($JP:4552) announced an update on their ongoing clinical study. The...

21d ago

JCR Pharmaceuticals Corrects Q1 FY2025 Results While Maintaining Full-Year Profit Outlook

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an update. JCR Pharmaceuticals has issued a partial correction...

2M ago

4552

JCR Pharmaceuticals Issues Partial Corrections to FY2024 Consolidated Results Amid Challenging Year

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has issued an announcement. JCR Pharmaceuticals Co., Ltd., a global specialty...

2M ago

4552

JCR Pharmaceuticals Corrects Interim Results but Confirms FY2025 Outlook and Dividend Plan

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an announcement. JCR Pharmaceuticals Co., Ltd., a Japan-based specialty...

2M ago

4552

JCR Pharmaceuticals Revises Past Financial Results After Accounting Error Review

JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ) has shared an update. JCR Pharmaceuticals has announced partial corrections to...

2M ago

4552

JCR Pharmaceuticals Corrects Nine-Month FY2025 Earnings Disclosure

The latest update is out from JCR Pharmaceuticals Co., Ltd. ( ($JP:4552) ). JCR Pharmaceuticals, a Japan-based specialty...

2M ago

4552

4552 FAQ

What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?

JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥444.00 and its highest was ¥824.00 in the past 12 months.

What is JCR Pharmaceuticals Co., Ltd.’s market cap?

JCR Pharmaceuticals Co., Ltd.’s market cap is ¥56.43B.

When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?

JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is Jul 29, 2026 which is in 27 days.

How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?

JCR Pharmaceuticals Co., Ltd. released its earnings results on May 13, 2026. The company reported ¥3.57 earnings per share for the quarter, beating the consensus estimate of -¥6.628 by ¥10.198.

Is JCR Pharmaceuticals Co., Ltd. overvalued?

According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does JCR Pharmaceuticals Co., Ltd. pay dividends?

JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥9.922 which represents an annual dividend yield of 2.71%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here

What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?

JCR Pharmaceuticals Co., Ltd.’s EPS estimate is -11.27.

How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?

JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.

What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?

JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥3.57 in its last earnings report, beating expectations of -¥6.628. Following the earnings report the stock price went up 0.896%.

Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4552

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

JCR Pharmaceuticals Co., Ltd.

JCR Pharmaceuticals Co., Ltd. is a specialized pharmaceutical firm primarily engaged in the creation, development, manufacturing, international trade, and distribution of medicinal products, regenerative therapies, and active pharmaceutical ingredients within Japan. The company offers a range of therapeutic solutions, including GROWJECT, which addresses growth hormone deficiency and short stature; IZCARGO, prescribed for Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion, utilized in the management of Fabry disease; and TEMCELL HS Inj, employed to treat acute graft-versus-host disease. Beyond its current offerings, JCR Pharmaceuticals is also developing Epoetin Alfa BS and Darbepoetin Alfa BS Injections, both intended for the treatment of renal anemia. Furthermore, the company markets various medical devices and laboratory instruments. Founded in 1975, its headquarters are situated in Ashiya, Japan.

JCR Pharmaceuticals Co., Ltd. (4552) Earnings & Revenues

Historic Earnings Reports

4552 Stock 12 Month Forecast

Average Price Target

¥560.00

▼(-21.35% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"429":"¥429","547":"¥547","665":"¥665","783":"¥783","901":"¥901"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥900.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":560,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥560.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":430,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥430.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[429,547,665,783,901],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,456,490.15384615384613,524.3076923076923,558.4615384615385,592.6153846153846,626.7692307692307,660.9230769230769,695.0769230769231,729.2307692307693,763.3846153846154,797.5384615384615,831.6923076923076,865.8461538461538,{"y":900,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,456,464,472,480,488,496,504,512,520,528,536,544,552,{"y":560,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,456,454,452,450,448,446,444,442,440,438,436,434,432,{"y":430,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":493.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":580.812,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":614.692,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":623.45,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":588.049,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":749.321,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":700.153,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":595.916,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":649.018,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":594,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":465,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":456,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >